• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by AC Immune SA

    AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Announces Upcoming Presentations at AD/PD™ 2024
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune to Regain Global Rights to Crenezumab and Semorinemab
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Announces Pricing of Underwritten Offering of Common Shares
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune to Present at the Jefferies 2023 London Healthcare Conference
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune SA Appoints New Chief Medical Officer
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Showcasing Precision Medicine Programs at AAIC 2023
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Holds Annual General Meeting of Shareholders
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    Tickers ACIU
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.